ChartRow logo
Data provided bySource: Twelve Data
RPRX
$68.68+0.23%
as of close, Nov 17, 2026
☾ AH $68.68 +0.23%
Share this page

RPRX — Royalty Pharma plc price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in RPRX be worth today? →
RPRX returns: By year · By month · By week · Trailing

Price data

Price
$68.68
YTD price return
+77.74%
YTD total return
+80.80%
Market cap
39.4B
Enterprise value
50.4B
Shares outstanding
573.6M
52W low
$37.31
52W high
$70.37
From 52W high
-2.40%
From 52W low
+84.08%
52W range
95%$37.31–$70.37
Beta
0.42

Volume

Rel volume
0.78×
30D volume
3.4M
30D $ vol
217.2M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
−$6.3M
Insider net 1Y
−$62.5M

Form 4 transactions by trade date, as filed; latest on file 2026-10-05.

Fundamentals

Sales (ttm)
2.6B
Sales/share
$4.56
EPS (ttm)
$1.17
Book value/share
$11.92
Net margin
25.70%
ROE
9.84%
ROA
3.46%
Debt / equity
1.11×
Current ratio
1.29

Growth (CAGR, ttm) · 10Y

Sales
+11.37%+4.03%+2.74%n/a
Net income
-11.99%+53.90%-3.00%n/a
Shares
-0.63%-1.35%-1.13%n/a

Per-share growth (CAGR, ttm) · 10Y

EPS
-6.81%+161.04%+6.16%n/a
Sales/share
+12.08%+5.45%+3.92%n/a
Book value/share
+7.27%+5.07%+4.55%n/a
Dividend/share
+6.33%+6.30%+6.70%n/a
Price
+75.45%+37.18%+10.09%n/a
Total return
+78.47%+40.54%+12.77%n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
58.6×
P/OI (ttm)
26.3×
Fwd P/E
11.6×
P/S (ttm)
15.1×
P/B (mrq)
5.8×
EV/EBITDA (fy)
33.6×
EV/Sales (ttm)
19.3×
Dividend yield (fwd)Div yield
1.37%
Dividend yield (ttm)
1.37%
Dividend/share (fwd)
$0.94
Buyback yield (realized, 1y)
0.63%
Shareholder yield (realized, 1y)
2.00%
Buyback yield (cash, ttm)
0.66%
Shareholder yield (cash, ttm)
0.66%

Vs own 10Y history

P/E
83rd
P/OI
81st
P/S
100th
P/B
96th

Bar = where today’s multiple sits in RPRX’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-17#

Data provided bySource: Twelve Data
1D
+0.23%
5D
-1.11%
1M
+12.66%
3M
+15.53%
YTD
+77.74%
1Y
+75.38%
5Y
+61.68%
1D
+0.23%
5D
-0.77%
1M
+13.05%
3M
+15.92%
YTD
+80.80%
1Y
+78.40%
5Y
+82.34%

Fundamentals#

Revenue

5Y CAGR +2.3%5Y CAGR +2.3%YoY +13.3%
$2.6B TTM$690.1M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR −0.5%5Y CAGR −0.5%YoY −3.8%
$1.5B TTM$410.8M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +6.2%5Y CAGR +6.2%YoY −51.5%
$1.78 FY25$0.32 Q3 '26
FY20FY21FY22FY23FY24FY25
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR −4.6%5Y CAGR −4.6%YoY −49.1%
$672.5M TTM$144.7M Q3 '26
FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +50.3%5Y +50.3%YoY −0.5%
557.1M TTM557M Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Dividend per share

YoY +6.8%
$0.92 TTM$0.23 Q3 '26
FY20FY21FY22FY23FY24FY25TTM
Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Full RPRX financials →

Royalty Pharma plc Class A Ordinary Shares represents an equity interest in Royalty Pharma plc, a New York-based biopharmaceutical royalty company. The company acquires and manages royalty interests tied to approved medicines and development-stage therapies, providing financing to drug developers and rights holders in exchange for a share of future product sales. Its portfolio spans treatments in areas such as rare diseases, oncology, neuroscience, immunology, hematology, respiratory disease, infectious disease, and diabetes. Royalty Pharma also supports innovation by partnering with biotechnology and pharmaceutical companies, academic institutions, and research organizations across the life sciences sector. Through this model, the company serves as a specialized capital provider in the healthcare market, linking long-term funding needs with recurring revenue streams from commercialized therapies and pipeline assets.

New York, NY·100 employees·Biotechnology·royaltypharma.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding RPRX#

18 of the 193 ETFs ChartRow carries live hold RPRX. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
VXFVanguard Extended Market ETF0.3%
IWSiShares Russell Mid-Cap Value ETF0.2%
IWRiShares Russell Midcap ETF0.2%
VYMVanguard High Dividend Yield ETF0.1%
DGROiShares Core Dividend Growth ETF0.1%
VONVVanguard Russell 1000 Value ETF0.1%
IWDiShares Russell 1000 Value ETF0.1%
ONEQFidelity Nasdaq Composite Index ETF0.1%
TickerName1M1D
LLYEli Lilly and Company+12.61%-1.13%
JNJJohnson & Johnson+9.05%-1.36%
ABBVAbbVie Inc.+2.59%-0.59%
MRKMerck & Co. Inc.-1.77%-0.75%
UNHUnitedHealth Group Incorporated Common Stock (DE)-2.93%-5.42%
NVSNovartis AG+5.65%-0.67%
TMOThermo Fisher Scientific Inc.-0.47%-0.66%
AMGNAmgen Inc.+5.88%-0.95%